Minocycline Prevents IL-6 Increase after Acute Ischemic Stroke

Jeffrey A Switzer, Andrea Sikora, Adviye Ergul, Jennifer L Waller, David C Hess, Susan C. Fagan

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Higher levels of the inflammatory biomarker interleukin-6 (IL-6) correlate with poor clinical outcome in acute ischemic stroke (AIS). Minocycline (MC) is a known anti-inflammatory agent; thus, the effect of MC on IL-6 in the first 24 h of AIS was investigated to determine potential anti-inflammatory activity. The Minocycline to Improve Neurologic Outcome in Stroke (MINOS) study was a non-randomized dose-escalation (3.0-10.0 mg/kg) trial of IV MC for AIS within 6 h of onset. Plasma IL-6 samples were collected prior to MC treatment at 1, 24, and 72 h and compared to those collected in a separate observational study of blood biomarkers in AIS. IL-6 levels were measured by commercially available ELISA kits. The lower limit of detection for IL-6 was 1 pg/ml. Sixty MINOS subjects and 29 non-MINOS subjects were enrolled, and there was no difference in baseline stroke severity. There was no significant difference in IL-6 level pre-MC treatment at 1, 24, or 72 h. However, the odds of a non-detectable IL-6 at 24 h in MINOS were 8.94 (95% CI 2.62-30.46) compared with non-MINOS subjects. It is likely that even low doses of MC have a potent systemic anti-inflammatory effect in AIS. Whether this results in improved outcome will be tested in a randomized clinical trial.

Original languageEnglish (US)
Pages (from-to)364-368
Number of pages5
JournalTranslational Stroke Research
Volume3
Issue number3
DOIs
StatePublished - Sep 1 2012

Fingerprint

Minocycline
Interleukin-6
Stroke
Nervous System
Anti-Inflammatory Agents
Biomarkers
Observational Studies
Limit of Detection
Randomized Controlled Trials
Enzyme-Linked Immunosorbent Assay

Keywords

  • Acute cerebral infarction
  • Biomarkers
  • Emergency treatment of stroke
  • Inflammation
  • Interleukin-6

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)
  • Cardiology and Cardiovascular Medicine

Cite this

Minocycline Prevents IL-6 Increase after Acute Ischemic Stroke. / Switzer, Jeffrey A; Sikora, Andrea; Ergul, Adviye; Waller, Jennifer L; Hess, David C; Fagan, Susan C.

In: Translational Stroke Research, Vol. 3, No. 3, 01.09.2012, p. 364-368.

Research output: Contribution to journalArticle

@article{5bf8dd2a1df144ecbb6f3437816b0dc0,
title = "Minocycline Prevents IL-6 Increase after Acute Ischemic Stroke",
abstract = "Higher levels of the inflammatory biomarker interleukin-6 (IL-6) correlate with poor clinical outcome in acute ischemic stroke (AIS). Minocycline (MC) is a known anti-inflammatory agent; thus, the effect of MC on IL-6 in the first 24 h of AIS was investigated to determine potential anti-inflammatory activity. The Minocycline to Improve Neurologic Outcome in Stroke (MINOS) study was a non-randomized dose-escalation (3.0-10.0 mg/kg) trial of IV MC for AIS within 6 h of onset. Plasma IL-6 samples were collected prior to MC treatment at 1, 24, and 72 h and compared to those collected in a separate observational study of blood biomarkers in AIS. IL-6 levels were measured by commercially available ELISA kits. The lower limit of detection for IL-6 was 1 pg/ml. Sixty MINOS subjects and 29 non-MINOS subjects were enrolled, and there was no difference in baseline stroke severity. There was no significant difference in IL-6 level pre-MC treatment at 1, 24, or 72 h. However, the odds of a non-detectable IL-6 at 24 h in MINOS were 8.94 (95{\%} CI 2.62-30.46) compared with non-MINOS subjects. It is likely that even low doses of MC have a potent systemic anti-inflammatory effect in AIS. Whether this results in improved outcome will be tested in a randomized clinical trial.",
keywords = "Acute cerebral infarction, Biomarkers, Emergency treatment of stroke, Inflammation, Interleukin-6",
author = "Switzer, {Jeffrey A} and Andrea Sikora and Adviye Ergul and Waller, {Jennifer L} and Hess, {David C} and Fagan, {Susan C.}",
year = "2012",
month = "9",
day = "1",
doi = "10.1007/s12975-012-0150-4",
language = "English (US)",
volume = "3",
pages = "364--368",
journal = "Translational Stroke Research",
issn = "1868-4483",
publisher = "Springer US",
number = "3",

}

TY - JOUR

T1 - Minocycline Prevents IL-6 Increase after Acute Ischemic Stroke

AU - Switzer, Jeffrey A

AU - Sikora, Andrea

AU - Ergul, Adviye

AU - Waller, Jennifer L

AU - Hess, David C

AU - Fagan, Susan C.

PY - 2012/9/1

Y1 - 2012/9/1

N2 - Higher levels of the inflammatory biomarker interleukin-6 (IL-6) correlate with poor clinical outcome in acute ischemic stroke (AIS). Minocycline (MC) is a known anti-inflammatory agent; thus, the effect of MC on IL-6 in the first 24 h of AIS was investigated to determine potential anti-inflammatory activity. The Minocycline to Improve Neurologic Outcome in Stroke (MINOS) study was a non-randomized dose-escalation (3.0-10.0 mg/kg) trial of IV MC for AIS within 6 h of onset. Plasma IL-6 samples were collected prior to MC treatment at 1, 24, and 72 h and compared to those collected in a separate observational study of blood biomarkers in AIS. IL-6 levels were measured by commercially available ELISA kits. The lower limit of detection for IL-6 was 1 pg/ml. Sixty MINOS subjects and 29 non-MINOS subjects were enrolled, and there was no difference in baseline stroke severity. There was no significant difference in IL-6 level pre-MC treatment at 1, 24, or 72 h. However, the odds of a non-detectable IL-6 at 24 h in MINOS were 8.94 (95% CI 2.62-30.46) compared with non-MINOS subjects. It is likely that even low doses of MC have a potent systemic anti-inflammatory effect in AIS. Whether this results in improved outcome will be tested in a randomized clinical trial.

AB - Higher levels of the inflammatory biomarker interleukin-6 (IL-6) correlate with poor clinical outcome in acute ischemic stroke (AIS). Minocycline (MC) is a known anti-inflammatory agent; thus, the effect of MC on IL-6 in the first 24 h of AIS was investigated to determine potential anti-inflammatory activity. The Minocycline to Improve Neurologic Outcome in Stroke (MINOS) study was a non-randomized dose-escalation (3.0-10.0 mg/kg) trial of IV MC for AIS within 6 h of onset. Plasma IL-6 samples were collected prior to MC treatment at 1, 24, and 72 h and compared to those collected in a separate observational study of blood biomarkers in AIS. IL-6 levels were measured by commercially available ELISA kits. The lower limit of detection for IL-6 was 1 pg/ml. Sixty MINOS subjects and 29 non-MINOS subjects were enrolled, and there was no difference in baseline stroke severity. There was no significant difference in IL-6 level pre-MC treatment at 1, 24, or 72 h. However, the odds of a non-detectable IL-6 at 24 h in MINOS were 8.94 (95% CI 2.62-30.46) compared with non-MINOS subjects. It is likely that even low doses of MC have a potent systemic anti-inflammatory effect in AIS. Whether this results in improved outcome will be tested in a randomized clinical trial.

KW - Acute cerebral infarction

KW - Biomarkers

KW - Emergency treatment of stroke

KW - Inflammation

KW - Interleukin-6

UR - http://www.scopus.com/inward/record.url?scp=84865746621&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865746621&partnerID=8YFLogxK

U2 - 10.1007/s12975-012-0150-4

DO - 10.1007/s12975-012-0150-4

M3 - Article

VL - 3

SP - 364

EP - 368

JO - Translational Stroke Research

JF - Translational Stroke Research

SN - 1868-4483

IS - 3

ER -